

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

**POSITIVE PROFIT ALERT**

This announcement is made by Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to inform the shareholders of the Company and potential investors that for the six months ended 30 June 2021, the Group is expected to record:

- (i) a revenue of approximately HK\$737.4 million against approximately HK\$323.8 million for the corresponding period in 2020, representing an increase of approximately 127.7%; and
- (ii) an increase of not less than 225% in the net profit as compared to the corresponding period in 2020.

The significantly improved financial results for the six months ended 30 June 2021 is a testament that the Group’s business is resilient and has been performing at the pre-COVID-19 level after the normalcy of the clinical operations of hospitals in the People’s Republic of China since September 2020.

The information contained in this announcement is based on the Board's preliminary assessment after reviewing the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 and the information currently available to the management of the Group as at the date of this announcement, which have not been reviewed or audited by the independent auditors and/or the audit committee of the Company. The information contained in this announcement do not constitute, represent or indicate the Group's total revenue or full financial performance and the information contained in this announcement may be subject to change and adjustment. Shareholders and potential investors are advised to refer to the results announcement of the Company for the six months ended 30 June 2021, which is expected to be published by the end of August 2021 in accordance with the requirements of the Listing Rules.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 20 July 2021

*Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.*